December 9th 2024
In research involving over 2,200 women who had SPECT MPI exams, researchers found that those who had a high score with the COronary Risk Score in WOmen (CORSWO) model had a greater than fourfold higher risk of major adverse coronary events (MACE).
Clinical Vignettes™: The Experts Explain How They Integrate PET Imaging into Metastatic HR+ Breast Cancer Care Settings
View More
School of Breast Oncology® Live Video Webcast: Clinical Updates from San Antonio
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
Clinical Case Vignette Series™: 41st Annual Miami Breast Cancer Conference®
View More
New Study Shows Non-Radiologists Interpreting 28 Percent of Imaging for Medicare Patients
June 28th 2024While radiologists interpreted approximately 99 percent of all non-cardiac CT, MRI and nuclear medicine studies in hospital and emergency department settings for Medicare beneficiaries, new research shows significantly less radiologist review of cardiac imaging and office-based imaging.
Study Shows PET/CT is Superior to SPECT/CT in Managing Patients with Primary Hyperparathyroidism
June 21st 2024F18-choline PET/CT imaging guidance for minimally invasive parathyroidectomy (MIP) procedures led to a 29 percent higher percentage of normocalcemia at one month post-op in comparison to imaging guidance with Tc99m-sestaMIBI (MIBI) SPECT/CT, according to new research.
Can Deep Learning Automate Amyloid Positivity Assessment on Brain PET Imaging?
June 14th 2024In validation testing with 205 18F florbetapir PET scans from 95 patients with Alzheimer’s disease, a deep learning model demonstrated a 93.2 percent accuracy rate and a 97 percent AUC for detecting amyloid-β positivity.
SNMMI: Can Ultra-Low Dose PET Supplant the Need for CT Attenuation Correction?
June 11th 2024Ultra-low dosing with long axial field-of-view positron emission tomography (PET) scanners facilitates qualitative PET imaging at a more than 50 percent reduction of conventional radiation dosing with PET, according to new research presented at the SNMMI 2024 conference.
SNMMI: AI May Enhance Detection and Risk Assessment for Multiple Cancers on Whole-Body PET/CT Scans
June 10th 2024Deep transfer learning may elevate the capability of whole-body PET/CT scans to diagnose multiple cancers, ranging from breast cancer and lung cancer to melanoma and prostate cancer, according to new research presented at the SNMMI conference.
Siemens Healthineers Announces FDA Clearance for New PET/CT System at SNMMI Meeting
June 9th 2024Emphasizing enhanced time-of-flight performance and an energy-efficient design, the Biograph Trinion PET/CT system can reportedly be utilized for a variety of imaging needs, ranging from theranostic applications to neurology imaging.
SNMMI: Study Finds FAP-Targeted Radioligand Therapy Beneficial for Patients with Advanced Sarcomas
June 8th 2024The use of 90Y-FAPI-46 radioligand therapy resulted in controlled disease progression in nearly half of a 30-person cohort largely comprised of patients with advanced sarcomas, according to new research presented at the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting.
Meta-Analysis Assesses Impact of PSMA PET/CT for Staging of Renal Cell Carcinoma
May 24th 2024PSMA PET/CT demonstrated an 83 percent pooled detection rate for primary or metastatic renal cell carcinoma (RCC), and an 87 percent detection rate for restaging of metastatic or recurrent RCC, according to a nine-study meta-analysis.
Study: PSMA PET/CT Agent May Rule Out csPCa in 93 Percent of PI-RADS 3 Lesions
May 22nd 2024New prospective research examining the utility of 18F-PSMA-1007 PET/CT revealed comparable sensitivity to mpMRI for detecting clinically significant prostate cancer and a 17 percent higher specificity rate.
Emerging Perspectives on PSMA PET Radiotracers: An Interview with Kenneth J. Pienta, MD
April 24th 2024In a recent interview, Kenneth J. Pienta, M.D., discussed the impact of piflufolastat F18, current directions in research with other PSMA-targeted radiotracers and future possibilities for the role of PSMA PET in the imaging paradigm for prostate cancer.
PET Imaging Study Suggests Possible Chemotherapy-Free Pathway for Treating Early Breast Cancer
April 5th 2024Utilizing PET imaging to assess pathologic complete response to the combination of trastuzumab and pertuzumab for patients with HER2-positive breast cancer, researchers noted a 94.8 percent rate of invasive disease-free survival at three years.